The nations and regions highlighted above have adopted Treatment as Prevention as a strategy or have signed a Memorandums of Understanding with the BC-CfE and other partners affirming commitments to adopting the strategy. These include the province of British Columbia; the U.S. cities of San Francisco and Washington, DC; Brazil; China; France; Spain; Panama; South Africa; Swaziland; and the province of Queensland, Australia.
In 2006, Dr. Julio Montaner, director of the BC Centre for Excellence in HIV/AIDS published a seminal and landmark paper in the Lancet that called for global implementation of “Treatment as Prevention” as a means to dramatically curb HIV morbidity, mortality, and HIV transmission. TasP means expanding treatment coverage through highly active anti-retroviral therapy (HAART), a combination of antiretroviral drugs that fully suppress HIV replication. This renders the number of HIV viral copies present in a patient’s blood virtually undetectable. In May 2009, the government of British Columbia launched a staged implementation of TasP, which has since expanded to all of BC and beyond.
The concepts pioneered through TasP have gained international support. UNAIDS has adopted the 90-90-90 plan as an ambitious but reachable target. Under the program, by 2020, 90% of all people living with HIV will know their status, 90% of all people diagnosed with HIV infection will receive sustained antiretroviral therapy, and 90% of all people receiving antiretroviral therapy will have viral suppression. By 2030, UNAIDS hopes to end the global AIDS epidemic.
© Copyright BC Centre for Excellence in HIV/AIDS, St. Paul's Hospital
608–1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6
Tel: 604-806-8477 | Fax: 604-806-9044
info@cfenet.ubc.ca
Copyright © 2019, BC Centre for Excellence in HIV/AIDS